Multiply Labs develops modular robotic systems for manufacturing personalized pharmaceuticals and gene-modified cell therapies. The company's architecture deploys clusters of collaborative robot arms (cobots) working in parallel, integrating artificial intelligence to control production workflows. These systems target two core manufacturing challenges: reducing contamination risk from human handling and eliminating bottlenecks inherent to manual or semi-automated production lines. The technology has been designed for end-to-end automation of cell therapy manufacturing, from initial processing through final packaging.
The company's robotic clusters are built on modular principles, allowing configuration scaling based on production volume requirements. According to company metrics, the technology achieves a 74% reduction in manufacturing costs compared to conventional approaches, though specific throughput figures have not been disclosed. The systems produce both personalized pharmaceutical capsules and individualized cell therapies, addressing the unique manufacturing requirements of precision medicine where each production run may differ at the patient level. Multiply Labs has established partnerships with NVIDIA for AI capabilities and Universal Robots for cobot hardware, indicating a systems-integration approach rather than proprietary robotics development.
Led by CEO Fred Parietti and headquartered in the United States, Multiply Labs positions its technology for global deployment across the life sciences sector. The robotics platform addresses the inherent tension in cell therapy manufacturing between maintaining sterile conditions and achieving commercial-scale throughput - two requirements that traditionally push in opposite directions. By automating manual steps and reducing human intervention in cleanroom environments, the systems aim to make gene-modified cell therapies and personalized pharmaceuticals more economically viable for wider patient populations.